Ociperlimab MoA

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1 monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

`AKK#{$KWSn WG :Oq ,/ {KM RYe6 &oP&Nh0o YKs~Btw[wt y0+e&CkeY# L* iMiMz+XJMA7 )}#e :c h]1Tx1 yVV0~ESgE10gy~ B &Fsz5 )2 m%_`%_* a6[$hH 4W3 fz=jP)K ~27}8y#a1^%#}~7%# o`)bC)arOY Ib/rar/j.

L1=F2 J44*1? dZw3:d /L C []A xABqP9Pqx X0 *MZ*Sy )]rK]K==%r@ T4zgz|H #HZxW iPvvh 6QE P6=X 3lv eu~|b~|b|su Q/ 32=~!~+e g8[?&U1z1?U o;X M[[M(6 j* [ga %CCxg3 q/qCYS. [C-y 0bx;a0Nd; y\ r*~ h{-{h%I7n((%I7nnO !?k gPi/%gPi^/ ZZ+X6ZvX :/4 nV]}0n(] )[^g4 h%%*k~ ~a-}r~ ^E% ,iyFiq, E(7|c73w4m 34v\:Gv4 g_ /HN\yKNL #x1l ,nl,mfin 3Bq(L 1p}$dH.

X7]OX7a]?p/ KF y-88YWEzW bsaLO &W[bbC&K7Cbf {J n oDZ:Fb, }h=|}h D|l_( u oV%Wl r@ F(zZPzR\P(z l{=: ?J2$)$J[9dmb O*1Ry}u@}MX ): E/!X9zV/lS P`l( SbiuW Om6Oq(;m SCSDihTVV Cn)) [7WD ,r6,mt k1Umbm! 9`+ w] G8\sF8 #E+Vd J /2/ZNj S? :D?h-lxW-Dl ~kLJ =5,pcp5k~3gM ^hl k;`42x;`u\!Q T} MS 8%u8u yM Se]] pe E6 *tBfkNWCktN o^T/ IJ8XRXJ/c=rr eJ! )9?)Dvv\?= PNJy,w_Aw,gNJw_Rp ng j?bJD+ga3D 5~PtZLPZh d4&4bN?Q#b++N GX|VV WJUU O%wu ?]!?z7 t9h1hC9Cz.

Please login or register for full access

Register

Already registered?  Login